Hydroxyurea, crystalline powder

Supplier: MP BIOMEDICALS (FKA ICN BIOMED

Synonyms: N-(Aminocarbonyl)hydroxylamineHydroxycarbamide

0210202301 0210202310 0210202305 0210202325
IC10202305EA 162.65 USD
IC10202305 IC10202301 IC10202325 IC10202310
Hydroxyurea, crystalline powder
Hydroxyurea

Hydroxyurea is a inhibitor of DNA synthesis in vivo, and an antiviral and antineoplastic agent which is S-phase specific.


A ribonucleotide reductase inhibitor - inhibits by forming a free radical nitroxide that binds a tyrosyl free radical in the active site of the enzyme. Induces fetal hemoglobin production in sickle cell anemia patients.


Hydroxyurea induces apoptosis of in vitro myelogenous leukemia lymphocytes, and the phosphorylation of FADD and p53. It is also used to reduce the rate of painful attacks in sickle-cell disease and has antiretroviral properties in diseases such as AIDS.


Anti-neoplastic. Inactivates ribonucleoside reductase by forming a free radical nitroxide that binds a tyrosyl free radical in the active site of the enzyme. This blocks the synthesis of deoxynucleotides, which inhibits DNA synthesis and induces synchronization or cell death in S-phase.


Freely soluble in water (50 mg/mL-clear colorless solution) or hot alcohol.

Formula: CH₄N₂O₂
MW: 76.05 g/mol
Melting Pt: 136…146 °C
Storage Temperature: Ambient
MDL Number: MFCD00007943
CAS Number: 127-07-1
https://us.vwr.com/stibo/web/std.lang.all/33/63/36413363.jpg

Order Now

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR